Quotes 5-day view Delayed Nasdaq
08/09/2022
08/10/2022
08/11/2022
08/12/2022
08/15/2022
Date
0.8(c)
0.7893(c)
0.7581(c)
0.7999(c)
0.809(c)
Last
321 198
348 294
363 422
254 996
367 937
Volume
+0.90%
-1.34%
-3.95%
+5.51%
+1.14%
Change
Estimated financial data (e) (USD)
Sales 2022
-
-
-
Net income 2022
-188 M
-
-
Net cash position 2022
116 M
-
-
P/E ratio 2022
-0,43x
Yield 2022
-
Sales 2023
3,38 M
-
-
Net income 2023
-216 M
-
-
Net cash position 2023
100 M
-
-
P/E ratio 2023
-0,41x
Yield 2023
-
Capitalization
73,1 M
73,1 M
-
EV / Sales 2022
-
EV / Sales 2023
-8,01x
Nbr of Employees
213
Free-Float
93,4%
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as...
Ratings of Rubius Therapeutics, Inc.
All news about RUBIUS THERAPEUTICS, INC.
News in other languages on RUBIUS THERAPEUTICS, INC.
Analyst Recommendations on RUBIUS THERAPEUTICS, INC.
Chart RUBIUS THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends RUBIUS THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0,81 $
Average target price
6,80 $
Spread / Average Target
741%
Please enable JavaScript in your browser's settings to use dynamic charts.